Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 12 Researches
7.8
USERS' SCORE
Good
Based on 3 Reviews
8.2
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Choline (from 630 mg Choline Bitartrate)
250 mg
45%
Inositol
250 mg
†
Top Medical Research Studies
8
We examined the impact of a key sensor of endoplasmic reticulum stress, IRE1α, on obesity related to high-fat diets. By removing IRE1α specifically in microglial cells in male mice, we noticed a significant decrease in inflammation and metabolic dysfunction associated with diet-induced obesity. The results revealed that deleting IRE1α helped protect these male mice from weight gain and glucose intolerance. However, similar benefits were not found in female mice, indicating a gender-specific response to IRE1α deletion.
Read More
7
We explored the effects of myo-inositol (MI) supplementation on obesity in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). In this study, 51 newly diagnosed obese patients were randomly assigned to receive either MI or a placebo for eight weeks. Both groups received dietary recommendations during this time.
Our findings showed a notable decrease in weight for those taking MI compared to the placebo. Although both groups experienced significant reductions in obesity-related measures, the differences were only statistically significant for weight.
Interestingly, the study revealed that the MI group also had a greater decrease in their desire for fatty foods. Even when it came to oxidative stress markers like serum nitric oxide (NO), the MI group showed a more pronounced decrease. However, other oxidative stress biomarkers and antioxidant levels did not reveal any significant differences between the two groups by the end of the trial.
Overall, while MI supplementation didn't show dramatic improvements across all parameters, it did help with weight loss, reduced cravings for fatty foods, and lowered certain oxidative stress markers—suggesting potential benefits for managing obesity in the context of NAFLD.
Our findings showed a notable decrease in weight for those taking MI compared to the placebo. Although both groups experienced significant reductions in obesity-related measures, the differences were only statistically significant for weight.
Interestingly, the study revealed that the MI group also had a greater decrease in their desire for fatty foods. Even when it came to oxidative stress markers like serum nitric oxide (NO), the MI group showed a more pronounced decrease. However, other oxidative stress biomarkers and antioxidant levels did not reveal any significant differences between the two groups by the end of the trial.
Overall, while MI supplementation didn't show dramatic improvements across all parameters, it did help with weight loss, reduced cravings for fatty foods, and lowered certain oxidative stress markers—suggesting potential benefits for managing obesity in the context of NAFLD.
Read More
8
We conducted a double-blind, placebo-controlled study to explore how myo-inositol (MI) supplementation impacts insulin resistance (IR) in obese individuals suffering from non-alcoholic fatty liver disease (NAFLD). The study included 48 participants whose body mass index (BMI) ranged from 30 to 40 kg/m².
Participants were randomly assigned to receive either MI or a placebo for eight weeks. Throughout the study, we measured various health parameters, including weight, serum glucose levels, and IR indices. Most excitingly, our findings revealed that MI supplementation significantly increased the mRNA expression of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating insulin sensitivity.
Overall, we observed an improvement in insulin resistance among those receiving MI. All measured IR indices showed positive changes after MI supplementation, indicating potential benefits for obesity management in NAFLD patients. However, the quantitative insulin sensitivity check index (QUICKI) did not show significant improvement.
Through this research, we highlight the importance of myo-inositol as a promising adjunct therapy that might help improve metabolic health in individuals struggling with obesity and its related complications.
Participants were randomly assigned to receive either MI or a placebo for eight weeks. Throughout the study, we measured various health parameters, including weight, serum glucose levels, and IR indices. Most excitingly, our findings revealed that MI supplementation significantly increased the mRNA expression of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating insulin sensitivity.
Overall, we observed an improvement in insulin resistance among those receiving MI. All measured IR indices showed positive changes after MI supplementation, indicating potential benefits for obesity management in NAFLD patients. However, the quantitative insulin sensitivity check index (QUICKI) did not show significant improvement.
Through this research, we highlight the importance of myo-inositol as a promising adjunct therapy that might help improve metabolic health in individuals struggling with obesity and its related complications.
Read More
Most Useful Reviews
8
Improves stress resilience
Choline and inositol, belonging to the B vitamin group, significantly influence brain and nervous system health. Choline (vitamin B4) supports cognitive function, helps manage stress, and prevents depression. It promotes sleep quality and regulates glucose levels to avert diabetes. Additionally, choline boosts metabolism and liver function, aiding in obesity prevention. Inositol (vitamin B8) enhances brain performance and counters fatigue, helping maintain proper metabolism while benefitting skin health as well.
Read More
7.5
Cholesterol reduction
1 people found this helpful
Inositol is known as the "vitamin of youth" due to its role in fat metabolism regulation, lowering blood cholesterol levels, and hence reducing the risk of atherosclerosis and obesity. It also improves blood flow and prevents blood clot formation while maintaining artery wall elasticity.
Read More
6
Facilitates weight loss
2 people found this helpful
This combination with omega-3 and other nutrients has improved my mood and energy levels. After losing 2.5 kg, I’ve noticed it helps eliminate toxins and reduces liver obesity. I had issues with leptin and insulin resistance, but this approach is helping manage my appetite without antidepressants, leading to a better overall state.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 12 Researches
7.8
- All Researches
9
We aimed to evaluate the effects of a nutraceutical combination that includes myo-inositol, among other ingredients, on overweight individuals suffering from metabolic syndrome. This observational study involved 74 participants—50 females and 24 males—who followed a three-month regimen while maintaining their normal lifestyles.
Throughout the study, we observed promising results. After three months, there was a notable decrease in insulin levels, which is a positive sign for those struggling with insulin resistance. Body weight, BMI, abdominal circumference, and other metabolic markers such as total cholesterol and triglycerides also showed significant improvement.
While glucose levels trended lower, they did not demonstrate a significant change. Importantly, the study confirmed that there were no adverse side effects associated with this treatment. Overall, the nutraceutical combination seems to positively influence various metabolic parameters, suggesting potential benefits for individuals battling obesity related to metabolic syndrome, though the contribution of inositol alone remains unclear due to the blend with other agents.
Throughout the study, we observed promising results. After three months, there was a notable decrease in insulin levels, which is a positive sign for those struggling with insulin resistance. Body weight, BMI, abdominal circumference, and other metabolic markers such as total cholesterol and triglycerides also showed significant improvement.
While glucose levels trended lower, they did not demonstrate a significant change. Importantly, the study confirmed that there were no adverse side effects associated with this treatment. Overall, the nutraceutical combination seems to positively influence various metabolic parameters, suggesting potential benefits for individuals battling obesity related to metabolic syndrome, though the contribution of inositol alone remains unclear due to the blend with other agents.
Read More
9
Combined treatment shows promise
We conducted a study to explore how a combination of magnesium biotinate (MgB) and inositol-stabilized arginine silicate (ASI) impacts metabolic dysfunctions linked to obesity. Our experimental design involved 40 rats that were divided into five groups, with one group receiving a standard diet and others fed a high-fat diet. Some groups were supplemented with either MgB, ASI, or both to see how these substances might counteract issues associated with obesity.
What we found was quite intriguing. The combination of MgB and ASI was effective in reducing overall cholesterol levels, as well as lowering free fatty acids and malondialdehyde—an indicator of oxidative stress. We also observed a significant reduction in inflammatory markers in the liver, which are typically elevated in high-fat diet scenarios. Additionally, the antioxidant enzyme activities improved, which is vital for combating oxidative stress.
Furthermore, brain-derived neurotrophic factor, serotonin, and dopamine levels were also boosted through this treatment, suggesting a positive effect on brain chemistry. The combined treatment seemed to enhance the body's ability to manage lipids and counteract the effects of a high-fat diet.
However, it is important to note that while our results show promise for MgB and ASI, the study did not specifically isolate the effects of inositol alone. This lack of isolation makes it challenging to confirm its individual impact distinctly on obesity and its related metabolic disorders.
What we found was quite intriguing. The combination of MgB and ASI was effective in reducing overall cholesterol levels, as well as lowering free fatty acids and malondialdehyde—an indicator of oxidative stress. We also observed a significant reduction in inflammatory markers in the liver, which are typically elevated in high-fat diet scenarios. Additionally, the antioxidant enzyme activities improved, which is vital for combating oxidative stress.
Furthermore, brain-derived neurotrophic factor, serotonin, and dopamine levels were also boosted through this treatment, suggesting a positive effect on brain chemistry. The combined treatment seemed to enhance the body's ability to manage lipids and counteract the effects of a high-fat diet.
However, it is important to note that while our results show promise for MgB and ASI, the study did not specifically isolate the effects of inositol alone. This lack of isolation makes it challenging to confirm its individual impact distinctly on obesity and its related metabolic disorders.
Read More
9
We explored the effects of a food supplement containing glucomannan, D-chiro-inositol, blume, and inulin on individuals with metabolic syndrome (MetS). In this study, fifty-eight subjects with MetS, including those with type 2 diabetes or impaired glucose tolerance, participated in a randomized trial where they took the supplement daily for four months alongside their metformin treatment.
After the supplementation period, we observed significant improvements in various health markers. Participants experienced reductions in body weight and body mass index (BMI), along with lower serum insulin levels and improved insulin sensitivity, as indicated by a decrease in the HOMA index. Additionally, there were favorable changes in the lipid profile, including lower total cholesterol, triglycerides, and LDL cholesterol levels.
While our study supports the supplement’s overall effectiveness in managing obesity-related factors, it is important to note that inositol was part of a combination with other ingredients, making it difficult to isolate its specific impact. Nonetheless, the findings highlight a promising approach to help combat obesity in those with MetS through dietary supplementation.
After the supplementation period, we observed significant improvements in various health markers. Participants experienced reductions in body weight and body mass index (BMI), along with lower serum insulin levels and improved insulin sensitivity, as indicated by a decrease in the HOMA index. Additionally, there were favorable changes in the lipid profile, including lower total cholesterol, triglycerides, and LDL cholesterol levels.
While our study supports the supplement’s overall effectiveness in managing obesity-related factors, it is important to note that inositol was part of a combination with other ingredients, making it difficult to isolate its specific impact. Nonetheless, the findings highlight a promising approach to help combat obesity in those with MetS through dietary supplementation.
Read More
8
Effects of Inositol with Supplements
We examined the impact of a blend of carnitines, L-arginine, L-cysteine, and myo-inositol on metabolic and reproductive metrics in women with polycystic ovary syndrome (PCOS) who are overweight or obese. Our focus was on understanding how this combination might reshape insulin sensitivity and hormone levels.
Over a period of 12 weeks, we evaluated the effects of this daily oral regimen on various health markers. We observed significant improvements in several key areas, including insulin response and metabolic parameters.
Particularly, the treatment led to better insulin sensitivity, which was shown by reduced insulin and C-peptide responses during an oral glucose tolerance test. Furthermore, the treatment also positively affected hormone levels necessary for reproductive health.
While the results highlight noteworthy benefits, it’s important to recognize that myo-inositol was part of a multi-component treatment. Therefore, we can't isolate its specific effect on obesity in this context without further investigation.
Over a period of 12 weeks, we evaluated the effects of this daily oral regimen on various health markers. We observed significant improvements in several key areas, including insulin response and metabolic parameters.
Particularly, the treatment led to better insulin sensitivity, which was shown by reduced insulin and C-peptide responses during an oral glucose tolerance test. Furthermore, the treatment also positively affected hormone levels necessary for reproductive health.
While the results highlight noteworthy benefits, it’s important to recognize that myo-inositol was part of a multi-component treatment. Therefore, we can't isolate its specific effect on obesity in this context without further investigation.
Read More
8
We conducted a double-blind, placebo-controlled study to explore how myo-inositol (MI) supplementation impacts insulin resistance (IR) in obese individuals suffering from non-alcoholic fatty liver disease (NAFLD). The study included 48 participants whose body mass index (BMI) ranged from 30 to 40 kg/m².
Participants were randomly assigned to receive either MI or a placebo for eight weeks. Throughout the study, we measured various health parameters, including weight, serum glucose levels, and IR indices. Most excitingly, our findings revealed that MI supplementation significantly increased the mRNA expression of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating insulin sensitivity.
Overall, we observed an improvement in insulin resistance among those receiving MI. All measured IR indices showed positive changes after MI supplementation, indicating potential benefits for obesity management in NAFLD patients. However, the quantitative insulin sensitivity check index (QUICKI) did not show significant improvement.
Through this research, we highlight the importance of myo-inositol as a promising adjunct therapy that might help improve metabolic health in individuals struggling with obesity and its related complications.
Participants were randomly assigned to receive either MI or a placebo for eight weeks. Throughout the study, we measured various health parameters, including weight, serum glucose levels, and IR indices. Most excitingly, our findings revealed that MI supplementation significantly increased the mRNA expression of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating insulin sensitivity.
Overall, we observed an improvement in insulin resistance among those receiving MI. All measured IR indices showed positive changes after MI supplementation, indicating potential benefits for obesity management in NAFLD patients. However, the quantitative insulin sensitivity check index (QUICKI) did not show significant improvement.
Through this research, we highlight the importance of myo-inositol as a promising adjunct therapy that might help improve metabolic health in individuals struggling with obesity and its related complications.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
8
Improves stress resilience
Choline and inositol, belonging to the B vitamin group, significantly influence brain and nervous system health. Choline (vitamin B4) supports cognitive function, helps manage stress, and prevents depression. It promotes sleep quality and regulates glucose levels to avert diabetes. Additionally, choline boosts metabolism and liver function, aiding in obesity prevention. Inositol (vitamin B8) enhances brain performance and counters fatigue, helping maintain proper metabolism while benefitting skin health as well.
Read More
7.5
Cholesterol reduction
1 people found this helpful
Inositol is known as the "vitamin of youth" due to its role in fat metabolism regulation, lowering blood cholesterol levels, and hence reducing the risk of atherosclerosis and obesity. It also improves blood flow and prevents blood clot formation while maintaining artery wall elasticity.
Read More
6
Facilitates weight loss
2 people found this helpful
This combination with omega-3 and other nutrients has improved my mood and energy levels. After losing 2.5 kg, I’ve noticed it helps eliminate toxins and reduces liver obesity. I had issues with leptin and insulin resistance, but this approach is helping manage my appetite without antidepressants, leading to a better overall state.
Read More
Frequently Asked Questions
6
Facilitates weight loss
2 people found this helpful
This combination with omega-3 and other nutrients has improved my mood and energy levels. After losing 2.5 kg, I’ve noticed it helps eliminate toxins and reduces liver obesity. I had issues with leptin and insulin resistance, but this approach is helping manage my appetite without antidepressants, leading to a better overall state.
8
Improves stress resilience
Choline and inositol, belonging to the B vitamin group, significantly influence brain and nervous system health. Choline (vitamin B4) supports cognitive function, helps manage stress, and prevents depression. It promotes sleep quality and regulates glucose levels to avert diabetes. Additionally, choline boosts metabolism and liver function, aiding in obesity prevention. Inositol (vitamin B8) enhances brain performance and counters fatigue, helping maintain proper metabolism while benefitting skin health as well.
7.5
Cholesterol reduction
1 people found this helpful
Inositol is known as the "vitamin of youth" due to its role in fat metabolism regulation, lowering blood cholesterol levels, and hence reducing the risk of atherosclerosis and obesity. It also improves blood flow and prevents blood clot formation while maintaining artery wall elasticity.
9
We aimed to evaluate the effects of a nutraceutical combination that includes myo-inositol, among other ingredients, on overweight individuals suffering from metabolic syndrome. This observational study involved 74 participants—50 females and 24 males—who followed a three-month regimen while maintaining their normal lifestyles.
Throughout the study, we observed promising results. After three months, there was a notable decrease in insulin levels, which is a positive sign for those struggling with insulin resistance. Body weight, BMI, abdominal circumference, and other metabolic markers such as total cholesterol and triglycerides also showed significant improvement.
While glucose levels trended lower, they did not demonstrate a significant change. Importantly, the study confirmed that there were no adverse side effects associated with this treatment. Overall, the nutraceutical combination seems to positively influence various metabolic parameters, suggesting potential benefits for individuals battling obesity related to metabolic syndrome, though the contribution of inositol alone remains unclear due to the blend with other agents.
Throughout the study, we observed promising results. After three months, there was a notable decrease in insulin levels, which is a positive sign for those struggling with insulin resistance. Body weight, BMI, abdominal circumference, and other metabolic markers such as total cholesterol and triglycerides also showed significant improvement.
While glucose levels trended lower, they did not demonstrate a significant change. Importantly, the study confirmed that there were no adverse side effects associated with this treatment. Overall, the nutraceutical combination seems to positively influence various metabolic parameters, suggesting potential benefits for individuals battling obesity related to metabolic syndrome, though the contribution of inositol alone remains unclear due to the blend with other agents.
7
We explored the effects of myo-inositol (MI) supplementation on obesity in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). In this study, 51 newly diagnosed obese patients were randomly assigned to receive either MI or a placebo for eight weeks. Both groups received dietary recommendations during this time.
Our findings showed a notable decrease in weight for those taking MI compared to the placebo. Although both groups experienced significant reductions in obesity-related measures, the differences were only statistically significant for weight.
Interestingly, the study revealed that the MI group also had a greater decrease in their desire for fatty foods. Even when it came to oxidative stress markers like serum nitric oxide (NO), the MI group showed a more pronounced decrease. However, other oxidative stress biomarkers and antioxidant levels did not reveal any significant differences between the two groups by the end of the trial.
Overall, while MI supplementation didn't show dramatic improvements across all parameters, it did help with weight loss, reduced cravings for fatty foods, and lowered certain oxidative stress markers—suggesting potential benefits for managing obesity in the context of NAFLD.
Our findings showed a notable decrease in weight for those taking MI compared to the placebo. Although both groups experienced significant reductions in obesity-related measures, the differences were only statistically significant for weight.
Interestingly, the study revealed that the MI group also had a greater decrease in their desire for fatty foods. Even when it came to oxidative stress markers like serum nitric oxide (NO), the MI group showed a more pronounced decrease. However, other oxidative stress biomarkers and antioxidant levels did not reveal any significant differences between the two groups by the end of the trial.
Overall, while MI supplementation didn't show dramatic improvements across all parameters, it did help with weight loss, reduced cravings for fatty foods, and lowered certain oxidative stress markers—suggesting potential benefits for managing obesity in the context of NAFLD.
5
This study explored the effects of combined therapy with myo-inositol and zinc on insulin resistance in children and adolescents with obesity. We conducted a double-blind, randomized, placebo-controlled trial in Northern Italy. Involving 56 participants aged 10 to 18 years, the study aimed to assess the impact of this treatment on insulin resistance, glucose-insulin metabolism, and lipid profiles after three months of supplementation.
Participants were divided into two groups: one received myo-inositol, zinc, and plant-based galactooligosaccharides, while the other received a placebo. Despite our hopes, the results showed that while the treatment improved HDL cholesterol levels, it did not significantly reduce insulin resistance overall. However, we observed that subjects with more severe obesity did experience a greater reduction in fasting insulin and HOMA-IR compared to those in the placebo group, highlighting some potential positive effects for specific populations.
Ultimately, we found that myo-inositol and zinc supplementation may offer some benefits regarding lipid profiles and managing complications of obesity, particularly in children with severe obesity. We recommend further research with a larger sample size and longer duration to confirm these findings and better understand the role of myo-inositol in obesity management.
Participants were divided into two groups: one received myo-inositol, zinc, and plant-based galactooligosaccharides, while the other received a placebo. Despite our hopes, the results showed that while the treatment improved HDL cholesterol levels, it did not significantly reduce insulin resistance overall. However, we observed that subjects with more severe obesity did experience a greater reduction in fasting insulin and HOMA-IR compared to those in the placebo group, highlighting some potential positive effects for specific populations.
Ultimately, we found that myo-inositol and zinc supplementation may offer some benefits regarding lipid profiles and managing complications of obesity, particularly in children with severe obesity. We recommend further research with a larger sample size and longer duration to confirm these findings and better understand the role of myo-inositol in obesity management.
7
We conducted a detailed analysis to uncover the relationship between myo-inositol degradation by gut microbes and obesity. Through shotgun metagenomic sequencing, we examined a large group of 631 obese subjects alongside 374 normal-weight individuals. Our findings revealed that a particular cluster of gut bacteria, predominantly Megamonas, was more common among those with obesity.
Interestingly, we observed that the presence of Megamonas, along with genetic predispositions, appeared to synergistically increase the risk of obesity. We discovered that Megamonas rupellensis carries specific genes that help break down myo-inositol, a substance that can inhibit fatty acid absorption in our intestinal cells.
In experiments with mice, those given either M. rupellensis or a strain of E. coli that could also degrade myo-inositol showed higher lipid absorption in the intestines, leading to increased weight gain. Our research suggests that targeting the myo-inositol pathway may offer a new approach to obesity management. However, it's important to note that inositol's effects were part of a broader mix of contributing factors to obesity.
Interestingly, we observed that the presence of Megamonas, along with genetic predispositions, appeared to synergistically increase the risk of obesity. We discovered that Megamonas rupellensis carries specific genes that help break down myo-inositol, a substance that can inhibit fatty acid absorption in our intestinal cells.
In experiments with mice, those given either M. rupellensis or a strain of E. coli that could also degrade myo-inositol showed higher lipid absorption in the intestines, leading to increased weight gain. Our research suggests that targeting the myo-inositol pathway may offer a new approach to obesity management. However, it's important to note that inositol's effects were part of a broader mix of contributing factors to obesity.
References
- Genazzani AD, Battipaglia C, Foschi M, Semprini E, Aio C, et al. Improved insulin sensitivity and reproductive profile in overweight/obese PCOS patients undergoing integrative treatment with carnitines, L-arginine, L-cysteine and myo-inositol. Gynecol Endocrinol. 2025;41:2458710. doi:10.1080/09513590.2025.2458710
- Antoniotti V, Partenope C, Solito A, Mancioppi V, Baima J, et al. Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity. Diabetes Obes Metab. 2025;27:1932. doi:10.1111/dom.16185
- Ricottini L, Basciani S, Spizzichini ML, de Mattia D, Coniglio-Iannuzzi Delle Noci M, et al. The Effectiveness and Safety of a Nutraceutical Combination in Overweight Patients with Metabolic Syndrome. Nutrients. 2024;16. doi:10.3390/nu16233977
- Aghajani T, Arefhosseini S, Ebrahimi-Mameghani M, Safaralizadeh R. The effect of myo-inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD. Food Sci Nutr. 2024;12:7177. doi:10.1002/fsn3.4267
- Sahin K, Sahin E, Orhan C, Er B, Akoglan B, et al. The impact of magnesium biotinate and arginine silicate complexes on metabolic dysfunctions, antioxidant activity, inflammation, and neuromodulation in high-fat diet-fed rats. Clin Exp Med. 2024;24:176. doi:10.1007/s10238-024-01434-9
- Wu C, Yang F, Zhong H, Hong J, Lin H, et al. Obesity-enriched gut microbe degrades myo-inositol and promotes lipid absorption. Cell Host Microbe. 2024;32:1301. doi:10.1016/j.chom.2024.06.012
- Mainini G, Ercolano S, De Simone R, Iavarone I, Lizza R, et al. Dietary Supplementation of Myo-Inositol, Cocoa Polyphenols, and Soy Isoflavones Improves Vasomotor Symptoms and Metabolic Profile in Menopausal Women with Metabolic Syndrome: A Retrospective Clinical Study. Medicina (Kaunas). 2024;60. doi:10.3390/medicina60040598
- Rostami S, Arefhosseini S, Tutunchi H, Khoshbaten M, Ebrahimi-Mameghani M. Does myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?. Food Sci Nutr. 2024;12:1279. doi:10.1002/fsn3.3842
- Lyons-Reid J, Derraik JGB, Kenealy T, Albert BB, Ramos Nieves JM, et al. Impact of preconception and antenatal supplementation with myo-inositol, probiotics, and micronutrients on offspring BMI and weight gain over the first 2 years. BMC Med. 2024;22:39. doi:10.1186/s12916-024-03246-w
- Citarrella R, Chianetta R, Amodeo S, Mirarchi L, Licata A, et al. Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Blume and Inulin in Patients with Metabolic Syndrome. Nutrients. 2024;16. doi:10.3390/nu16020249
- Quotah OF, Andreeva D, Nowak KG, Dalrymple KV, Almubarak A, et al. Interventions in preconception and pregnant women at risk of gestational diabetes; a systematic review and meta-analysis of randomised controlled trials. Diabetol Metab Syndr. 2024;16:8. doi:10.1186/s13098-023-01217-4
- Stilgenbauer L, Chen Q, Pungi D, James N, Jayarathne H, et al. Microglial ER stress response via IRE1α regulates diet-induced metabolic imbalance and obesity in mice. Mol Metab. 2025;95:102128. doi:10.1016/j.molmet.2025.102128
